These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23826153)

  • 1. Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection.
    Keane C; O'Shea D; Reiberger T; Peck-Radosavljevic M; Farrell G; Bergin C; Gardiner CM
    PLoS One; 2013; 8(6):e66831. PubMed ID: 23826153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
    Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
    AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
    Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
    Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
    Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
    New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy.
    Dayyeh BK; Gupta N; Sherman KE; de Bakker PI; Chung RT;
    PLoS One; 2011; 6(10):e25753. PubMed ID: 22003405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.
    Rallón NI; Naggie S; Benito JM; Medrano J; Restrepo C; Goldstein D; Shianna KV; Vispo E; Thompson A; McHutchison J; Soriano V
    AIDS; 2010 May; 24(8):F23-9. PubMed ID: 20389235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
    Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF
    J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
    Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA
    J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon-α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C.
    Arends JE; van Assen S; Stek CJ; Wensing AM; Fransen JH; Schellens IM; Spijkers SN; Mudrikova T; van Baarle D; Sprenger HG; Hoepelman AI
    Antivir Ther; 2011; 16(7):979-88. PubMed ID: 22024513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.
    Mandorfer M; Neukam K; Rivero A; Puoti M; Boesecke C; Baumgarten A; Grzeszczuk A; Zangerle R; Ernst D; Rockstroh JK; Trauner M; Pineda JA; Peck-Radosavljevic M; Reiberger T
    Antivir Ther; 2014; 19(4):407-14. PubMed ID: 24342953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relating the outcome of HCV infection and different host SNP polymorphisms in a Majorcan population coinfected with HCV-HIV and treated with pegIFN-RBV.
    Matas M; Picornell A; Cifuentes C; Payeras A; Homar F; González-Candelas F; López-Labrador FX; Moya A; Ramon C; Castro JA
    Int Microbiol; 2014 Mar; 17(1):11-20. PubMed ID: 25296442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.
    Naggie S; Osinusi A; Katsounas A; Lempicki R; Herrmann E; Thompson AJ; Clark PJ; Patel K; Muir AJ; McHutchison JG; Schlaak JF; Trippler M; Shivakumar B; Masur H; Polis MA; Kottilil S
    Hepatology; 2012 Aug; 56(2):444-54. PubMed ID: 22331604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.
    Lin CY; Chen JY; Lin TN; Jeng WJ; Huang CH; Huang CW; Chang SW; Sheen IS
    PLoS One; 2011 Mar; 6(3):e18322. PubMed ID: 21479134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection.
    Neukam K; Munteanu D; Haubitz S; Mira JA; Ingiliz P; Rivero-Juárez A; Lutz T; de los Santos-Gil I; Scholten S; Márquez M; Rauch A; Rockstroh JK; Pineda JA
    Antivir Ther; 2015; 20(4):407-13. PubMed ID: 25470790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.
    Marchetti G; Nasta P; Bai F; Gatti F; Bellistrì GM; Tincati C; Borghi F; Carosi G; Puoti M; Monforte Ad
    PLoS One; 2012; 7(2):e32028. PubMed ID: 22363790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients.
    Rallon NI; Lopez-Fernandez LA; Garcia MI; Benguria A; Fiorante S; Soriano V; Benito JM
    AIDS; 2013 Mar; 27(5):687-96. PubMed ID: 23196939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.
    Bruno G; Fasano M; Saracino A; Volpe A; Bartolomeo N; Ladisa N; Maggi P; Monno L; Angarano G
    New Microbiol; 2015 Jan; 38(1):21-7. PubMed ID: 25742144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.
    de Castellarnau M; Aparicio E; Parera M; Franco S; Tural C; Clotet B; Martínez MA
    PLoS One; 2012; 7(2):e31016. PubMed ID: 22328925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
    Neukam K; Camacho A; Caruz A; Rallón N; Torres-Cornejo A; Rockstroh JK; Macías J; Rivero A; Benito JM; López-Cortés LF; Nattermann J; Gómez-Mateos J; Soriano V; Pineda JA
    J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.